Funded Tech Companies
Innocrin
Headquartered in Durham, Innocrin has funding from Lilly Ventures, Novartis Venture Fund and Eshelman Ventures.
Company Overview
Company Name
Innocrin
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
4505 Emperor Blvd. 315
Durham, NC 27703
USA
Durham, NC 27703
USA
Phone
Website
Email Address
Not Recorded
Company Background Information
Overview
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
4/16/2015
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fred Eshelman
Chief Financial Officer
Charles Osborne
Chief Medical Officer
Edwina Baskin-Bey
Company Investors
- Lilly Ventures
- Novartis Venture Fund
- Eshelman Ventures (Fred Eshelman)
- Hatteras Venture Partners
- Intersouth Partners
Browse more funded tech companies:
InnoCentive | Innocutis Holdings
Share this article
About Our VC Deals Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs